Get the Stockscreener App
565.40
1.18%
6.80
Idexx Laboratories Inc stock is traded at $565.40, with a volume of 311.01K.
It is up +1.18% in the last 24 hours and up +1.48% over the past month.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
See More
Previous Close:
$558.60
Open:
$561.93
24h Volume:
311.01K
Relative Volume:
0.50
Market Cap:
$44.61B
Revenue:
$4.45B
Net Income/Loss:
$1.10B
P/E Ratio:
41.60
EPS:
13.591
Net Cash Flow:
$1.06B
1W Performance:
+1.32%
1M Performance:
+1.48%
6M Performance:
-20.77%
1Y Performance:
+4.45%
1-Day Range:
$559.72
$573.02
1-Week Range:
$547.38
$577.15
52-Week Range:
$506.91
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
Name
Idexx Laboratories Inc
Sector
Industry
Phone
(207) 556-0300
Address
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, NTRA, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
565.58 | 44.06B | 4.45B | 1.10B | 1.06B | 13.59 |
TMO
Thermo Fisher Scientific Inc
|
525.60 | 194.99B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
198.67 | 138.71B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
271.44 | 40.37B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
133.77 | 37.73B | 7.23B | 1.41B | 1.09B | 4.979 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Neutral |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-31-25 | Upgrade | Stifel | Hold → Buy |
| Oct-01-25 | Initiated | UBS | Neutral |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-01-25 | Initiated | Jefferies | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | BTIG Research | Buy |
| Jan-30-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Dec-04-23 | Upgrade | Cleveland Research | Neutral → Buy |
| Aug-02-23 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Jul-25-22 | Downgrade | Stifel | Buy → Hold |
| Jul-21-22 | Upgrade | Goldman | Neutral → Buy |
| Jul-12-22 | Initiated | Piper Sandler | Overweight |
| May-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-08-22 | Initiated | Atlantic Equities | Overweight |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-17-21 | Initiated | Barclays | Overweight |
| Sep-09-19 | Initiated | Goldman | Neutral |
| May-23-19 | Initiated | Guggenheim | Buy |
| Nov-02-18 | Reiterated | BofA/Merrill | Buy |
| May-07-18 | Reiterated | Stifel | Buy |
| Jan-16-18 | Initiated | Piper Jaffray | Overweight |
| Aug-23-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-28-17 | Upgrade | CL King | Neutral → Buy |
| Feb-03-17 | Downgrade | Feltl & Co. | Hold → Sell |
| Sep-29-16 | Resumed | BofA/Merrill | Neutral |
| Aug-16-16 | Reiterated | Stifel | Buy |
| Aug-03-16 | Upgrade | Northcoast | Sell → Neutral |
| Jul-20-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-19-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-01-16 | Initiated | CL King | Neutral |
| Mar-21-16 | Reiterated | Stifel | Buy |
| Feb-04-16 | Initiated | Credit Suisse | Outperform |
| Oct-29-15 | Reiterated | Stifel | Buy |
| Aug-28-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-13-15 | Reiterated | Stifel | Buy |
| Jul-23-15 | Reiterated | Canaccord Genuity | Buy |
View All
Idexx Laboratories Inc Stock (IDXX) Latest News
IDEXX Laboratories focuses on diagnostics growth. Investors watch demand trends - ad-hoc-news.de
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IDEXX Laboratories extends its diagnostics reach as a key S&P 500 health-tech name - ad-hoc-news.de
IDEXX Laboratories Does Not Need More Vet Visits, But It Needs More Tests Per Visit (IDXX) - Seeking Alpha
IDEXX Laboratories focuses on diagnostics growth. Business model supports long-term demand - Ad-hoc-news.de
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Laboratories Stock: $876 Target Backed by Cancer Dx Adoption Across 7,500 Practices - TIKR.com
IDEXX Laboratories stock holds its focus on diagnostics. Investors watch the business mix. - AD HOC NEWS
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Exploring a Potential 27% Upside for Investors - DirectorsTalk Interviews
IDEXX Laboratories stock tracks its core diagnostics business - AD HOC NEWS
IDXXIdexx Laboratories Inc Volatility & Greeks - Finviz
Enterprise value to EBIT forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
IDEXX Laboratories stock leans on its diagnostics base - Ad-hoc-news.de
Price to sales forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
Does IDEXX Laboratories (NASDAQ:IDXX) Deserve A Spot On Your Watchlist? - Moomoo
EULAV Asset Management's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus
IDEXX Laboratories Inc (IDXX) Stock Up 3.8% and Still Undervalued -- GF Score: 96/100 - GuruFocus
IDEXX Laboratories to Release 2026 Second Quarter Financial Results - 01net
Press Release: IDEXX Laboratories to Release 2026 Second Quarter Financial Results - 富途牛牛
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
IDEXX Laboratories Inc. stock underperforms Monday when compared to competitors - MarketWatch
IDEXX Laboratories, Inc.(NasdaqGS: IDXX) added to Russell Midcap Value Benchmark - marketscreener.com
Is the Options Market Predicting a Spike in IDEXX Laboratories Stock? - Zacks Investment Research
Is IDEXX Laboratories stock underperforming the Nasdaq? - MSN
IDEXX Laboratories (IDXX) Stock Analysis: Uncovering a Potential 28.58% Upside for Investors - DirectorsTalk Interviews
IDEXX Laboratories with a clear strategy focus, shares anchored in the NASDAQ-100 - AD HOC NEWS
IDEXX Laboratories, Inc.(NasdaqGS: IDXX) added to Russell 1000 Value Benchmark - marketscreener.com
The Catalyst Dx from IDEXX Laboratories Inc.compact chemistry analyzer for fast in-clinic results - AD HOC NEWS
IDEXX Laboratories, Inc.(NasdaqGS: IDXX) added to Russell 1000 Dynamic Index - marketscreener.com
IDEXX Laboratories opens the week with a clear consensus, NASDAQ-100 shares in a steady trend - Ad-hoc-news.de
IDEXX Laboratories focuses on long-term growth, shares in NASDAQ-100 healthcare peer group - Ad-hoc-news.de
New diagnostic test for kidney injury - DVM360
IDEXX Laboratories opens the week with earnings focus, shares steady - Ad-hoc-news.de
IDEXX Laboratories, Inc. Actuals & Estimates (NASDAQ:IDXX) - TradingView
IDEXX Laboratories, Inc. Actuals & Estimates (VIE:IDXX) - TradingView
IDXX Forecast — Price Target — Prediction for 2027 - TradingView
IDEXX Laboratories sets the pace with raised 2026 guidance, analysts back the stock - Ad-hoc-news.de
Enterprise value to EBITDA forward of IDEXX Laboratories, Inc. – DUS:IX1 - TradingView
Why IDEXX Laboratories Stock Looks Undervalued After Raising Its 2026 EPS Outlook to $15 - TIKR.com
Are IDEXX Laboratories’ (IDXX) New SDMA and Tapeworm Tests Deepening Its Diagnostics Moat? - Sahm
IDEXX Laboratories Inc (IDXX) Institutional Confidence - TradingKey
Price to book forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
Enterprise value to revenue forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
IDEXX Laboratories analyst consensus stays firm, shares trade below recent high - Ad-hoc-news.de
IDEXX Laboratories Inc (IDXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SNAP 4Dx Plus Test from IDEXX Laboratoriesquick tick-borne screening in minutes - Ad-hoc-news.de
Tranche Update on IDEXX Laboratories, Inc.'s Equity Buyback Plan announced on August 13, 1999. - marketscreener.com
A Small Upgrade Could Have a Big Impact for IDEXX Customers - Insider Monkey
IDEXX Laboratories StockSaturday deep dive into the long-term business model - Ad-hoc-news.de
IDEXX Laboratories Sharesanalyst consensus stays cautious - Ad-hoc-news.de
IDEXX Laboratories Stock Is Down 16% in 2026: Does the Q1 Beat Make It a Buy at $562? - TIKR.com
Idexx Laboratories Inc Stock (IDXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.85%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):